Biomarkers: how molecular data becomes a clinical decision

Think of a car dashboard. A warning light tells you what may be happening inside the engine without opening it. A biomarker works similarly: it is a measurable signal in the body—such as a protein, gene or mutation—that provides information about an internal process.

In medicine, that signal may serve very different purposes, which is where confusion often arises.

Not all biomarkers say the same thing

• Diagnostic biomarkers: help confirm whether a disease is present.
• Prognostic biomarkers: indicate how a disease may progress regardless of treatment.
• Predictive biomarkers: indicate whether a person is likely to respond well—or poorly—to a specific treatment.

Confusing these categories is more common than it seems, even in clinical settings, and may lead to misinterpretation.

A real example: breast cancer

HER2 helps classify some breast tumors and predicts which patients may benefit from therapies directed at that protein. The same molecular finding can therefore have several layers of usefulness when interpreted in context.

Why does not every biomarker change treatment?

Association with a disease is not enough. A biomarker must pass rigorous studies showing that acting on it improves real patient outcomes. Many promising research biomarkers do not yet have that evidence.

The central idea

Molecular data alone is not a medical decision. It gains value only when interpreted alongside clinical history, other tests and strong evidence. This is where science and clinical practice must work together.

This article provides general educational information and does not replace an individual medical assessment.